Healthcare and life sciences in Southeast Asia is deploying AI faster than regulatory frameworks are stabilising around it. Diagnostic imaging AI, clinical decision-support tools, triage algorithms, and AI-assisted drug discovery are all in active clinical and commercial use. MAS, BNM, and sector regulators are developing guidance but none yet prescribes an insurance standard.
The coverage question sits between three traditional wordings. Medical malpractice covers clinical decision by the professional. Product liability covers device failure. Tech E&O covers software. AI liability falls somewhere in all three, and cleanly in none.
Who we work with
Hospitals and clinic groups deploying diagnostic AI. If your radiology, pathology, or triage workflow uses AI, the liability question when the AI is wrong is unresolved in your existing programme. Medical malpractice may contest coverage on grounds that the decision was algorithmic. Tech E&O may contest on grounds that the claim is clinical. AI liability cover is designed for this gap and is placed through specialist markets that understand both the clinical governance and the model behaviour.
Digital health and telemedicine platforms. Platforms using AI for symptom assessment, medication recommendations, or remote monitoring carry combined tech E&O and medical exposure. Regulatory risk (PDPA, sector-specific guidelines from MOH Singapore and MOH Malaysia) adds a compliance dimension that amplifies the insurance question, and the cover that responds to all three layers is not typically on the shelf at domestic carriers.
Pharma and biotech with AI in R&D. AI in drug discovery, trial design, and trial operations changes the liability profile of the R&D process. If AI-driven trial design produces a downstream liability, traditional clinical trials cover and product liability may not respond as expected. Specialist cover responds to this specifically and is increasingly a point of scrutiny in biotech capital raises.
Medical devices with AI or ML components. Regulatory classification of AI/ML-enabled medical devices is tightening globally (FDA AI/ML Software as a Medical Device framework, EU MDR AI provisions). For SEA manufacturers or distributors of these devices, the liability and recall profile is evolving and traditional product liability wordings may not keep pace with the regulatory baseline.
How Emerge approaches healthcare and life sciences
Emerge is the full-spectrum insurance and risk specialist for Southeast Asia's healthcare and life sciences sector. AI liability across diagnostic, clinical, and R&D contexts, algorithmic bias cover, and parametric cover for hospital continuity are where our specialist capability is concentrated.
These placements require underwriters who understand clinical governance and model behaviour together. That combination sits in a small number of specialist markets globally, and that is where our work is focused.
Request an emerging-risk exposure review for your healthcare business →
